Table 1 Patients’ characteristics, clinical manifestations and laboratory results in patients with Raynaud’s phenomenon
Variables | Patients with Raynaud’s phenomenon (N = 64) |
|---|---|
Characteristics | |
Age (years old) | 50.9 ± 14.4 |
Sex, female (N (%)) | 58 (90.6) |
Raynaud’s phenomenon duration (years) | 5.3 ± 7.7 |
Newly classified to systemic sclerosis by the 2013 ACR/EULAR classification criteria (N (%)) | 17 (26.5) |
Autoimmune disease accompanied (N (%)) | 33 (51.6) |
Sjögren syndrome | 15 (23.4) |
Systemic lupus erythematosus | 8 (12.5) |
Mixed connective tissue disease | 5 (7.8) |
Rheumatoid arthritis | 3 (4.7) |
Inflammatory myopathy | 2 (3.1) |
Clinical manifestations (N (%)) | |
Scleroderma (proximal) | 0 (0) |
Puffy finger | 34 (53.1) |
Sclerodactyly | 7 (10.9) |
Digital tip ulcer | 2 (3.1) |
Fingertip pitting scar | 0 (0) |
Telangiectasia | 7 (10.9) |
Abnormal nailfold capillaries | 46 (71.8) |
Pulmonary arterial hypertension | 1 (1.6) |
Interstitial lung disease | 5 (7.8) |
Autoantibodies (N (%)) | |
Antinuclear antibody (centromere) | 19 (29.7) |
Anti-centromere antibody | 22 (34.4) |
Anti-Scl-70 antibody | 2 (3.1) |